Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Mutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?

Literature DB >> 20460640

Mutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?

Doris Steinemann, Marcel Tauscher, Inka Praulich, Charlotte M Niemeyer, Christian Flotho, Brigitte Schlegelberger.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2010 PMID： 20460640 PMCID： PMC2930968 DOI： 10.3324/haematol.2010.024984

Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941

× No keyword cloud information.

12 in total

1. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans.

Authors: B J Reinhart; F J Slack; M Basson; A E Pasquinelli; J C Bettinger; A E Rougvie; H R Horvitz; G Ruvkun
Journal: Nature Date: 2000-02-24 Impact factor: 49.962

2. RAS is regulated by the let-7 microRNA family.

Authors: Steven M Johnson; Helge Grosshans; Jaclyn Shingara; Mike Byrom; Rich Jarvis; Angie Cheng; Emmanuel Labourier; Kristy L Reinert; David Brown; Frank J Slack
Journal: Cell Date: 2005-03-11 Impact factor: 41.582

3. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.

Authors: Yoshimasa Saito; Gangning Liang; Gerda Egger; Jeffrey M Friedman; Jody C Chuang; Gerhard A Coetzee; Peter A Jones
Journal: Cancer Cell Date: 2006-06 Impact factor: 31.743

Review 4. Hyperactive Ras in developmental disorders and cancer.

Authors: Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal: Nat Rev Cancer Date: 2007-04 Impact factor: 60.716

5. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada.

Authors: H Hasle; L D Wadsworth; B G Massing; M McBride; K R Schultz
Journal: Br J Haematol Date: 1999-09 Impact factor: 6.998

6. Novel genetic variants in miR-191 gene and familial ovarian cancer.

Authors: Jie Shen; Richard DiCioccio; Kunle Odunsi; Shashikant B Lele; Hua Zhao
Journal: BMC Cancer Date: 2010-02-18 Impact factor: 4.430

7. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

Authors: Junichi Takamizawa; Hiroyuki Konishi; Kiyoshi Yanagisawa; Shuta Tomida; Hirotaka Osada; Hideki Endoh; Tomoko Harano; Yasushi Yatabe; Masato Nagino; Yuji Nimura; Tetsuya Mitsudomi; Takashi Takahashi
Journal: Cancer Res Date: 2004-06-01 Impact factor: 12.701

8. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.

Authors: Lena J Chin; Elena Ratner; Shuguang Leng; Rihong Zhai; Sunitha Nallur; Imran Babar; Roman-Ulrich Muller; Eva Straka; Li Su; Elizabeth A Burki; Richard E Crowell; Rajeshvari Patel; Trupti Kulkarni; Robert Homer; Daniel Zelterman; Kenneth K Kidd; Yong Zhu; David C Christiani; Steven A Belinsky; Frank J Slack; Joanne B Weidhaas
Journal: Cancer Res Date: 2008-10-15 Impact factor: 12.701

Mutations in the let-7 binding site - a mechanism of RAS activation in juvenile myelomonocytic leukemia?

1. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans.

2. RAS is regulated by the let-7 microRNA family.

3. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells.

Review 4. Hyperactive Ras in developmental disorders and cancer.

5. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada.

6. Novel genetic variants in miR-191 gene and familial ovarian cancer.

7. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival.

8. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk.

Review 9. Targeting RAS signaling pathways in juvenile myelomonocytic leukemia.

10. Germline mutation of microRNA-125a is associated with breast cancer.

1. Molecular targets for the treatment of juvenile myelomonocytic leukemia.

Review 2. MiRNA Dysregulation in Childhood Hematological Cancer.